Table 2 Patient characteristics of the two groups
Characteristics | Dose-reduced group | Dose-maintained group | Univariate analysis | |
|---|---|---|---|---|
n = 57 | n = 22 | p value | ||
Sex (men), n (%) | 38 (66.7) | 17 (77.3) | 0.42 | |
Mean age ± 2SD, year | 67.2 ± 9.7 | 62.1 ± 10.1 | 0.04 | |
Mean KPS ± 2SD, % | 91.1 ± 15.4 | 90.5 ± 14.6 | 0.87 | |
Mean BMI ± 2SD, kg/m2 | 21.9 ± 3.3 | 24.1 ± 4.5 | 0.05 | |
Mean BSA ± 2SD, m2 | 1.6 ± 0.2 | 1.7 ± 0.2 | <0.01 | |
Concomitant CYP3A4 metabolized drug, n (%) | 27 (47) | 12 (55) | 0.62 | |
MSKCC risk score, n Favorable/Intermediate/Poor | 4/36/17 | 2/14/6 | 0.94 | |
Histological clear cell subtype, n (%) | 32 (56) | 15 (68) | 0.77 | |
Prior nephrectomy, n (%) | 29 (51) | 12 (55) | 0.90 | |
Common sites of metastasis, n (%) | Lung | 29 (51) | 16 (73) | 0.13 |
Bone | 15 (26) | 5 (23) | 1.00 | |
Liver | 6 (11) | 2 (9) | 1.00 | |
Lymph node | 18 (32) | 6 (27) | 0.79 | |
Starting dose 50/37.5/25 mg, % | 72/21/7 | 68/14/18 | 0.29 | |
RDI during the first two weeks of dosing, mean ± 2SE, % | 83.9 ± 2.6 | 87.5 ± 4.2 | 0.47 | |
RDI during the last two weeks of dosing, mean ± 2SE, % | 31.0 ± 3.4 | 88.6 ± 5.5 | <0.01 |